GAITHERSBURG, Md., Oct. 24, 2019 /PRNewswire/ — MaxCyte, the global cell-based therapies and life sciences company, announces today that, having completed dosing of the second cohort of patients, clinical investigators have initiated dosing in the third cohort of patients of MaxCyte’s Phase I clinical trial with the next higher cell dose of MCY-M11. This lead, wholly-owned, non-viral mRNA-based cell therapy candidate from MaxCyte’s CARMA platform is a mesothelin-targeting chimeric antigen receptor (CAR) therapy being tested in individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma.
{iframe}https://www.prnewswire.com/news-releases/maxcyte-advances-phase-i-clinical-trial-of-lead-carma-mrna-based-cell-therapy-to-third-cohort-of-patients-300944593.html?tc=eml_cleartime{/iframe}